Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNLI NASDAQ:ESPR NYSE:RCUS NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$19.37+3.9%$19.74$12.58▼$23.77$3.07B0.991.73 million shs385,724 shsESPREsperion Therapeutics$3.13$2.58$0.79▼$4.18$805.76M0.918.76 million shs1.55 million shsRCUSArcus Biosciences$23.49+0.3%$23.36$7.91▼$28.72$2.95B0.871.19 million shs61,549 shsTLXTelix Pharmaceuticals$9.57+1.1%$9.89$6.28▼$18.49$3.25B0.08217,361 shs30,771 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics0.00%+1.30%-6.19%-13.02%+38.90%ESPREsperion Therapeutics0.00%0.00%+63.87%-5.15%+296.05%RCUSArcus Biosciences0.00%+0.21%-7.56%+16.22%+159.55%TLXTelix Pharmaceuticals0.00%-7.88%-10.32%+44.58%-42.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$19.37+3.9%$19.74$12.58▼$23.77$3.07B0.991.73 million shs385,724 shsESPREsperion Therapeutics$3.13$2.58$0.79▼$4.18$805.76M0.918.76 million shs1.55 million shsRCUSArcus Biosciences$23.49+0.3%$23.36$7.91▼$28.72$2.95B0.871.19 million shs61,549 shsTLXTelix Pharmaceuticals$9.57+1.1%$9.89$6.28▼$18.49$3.25B0.08217,361 shs30,771 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics0.00%+1.30%-6.19%-13.02%+38.90%ESPREsperion Therapeutics0.00%0.00%+63.87%-5.15%+296.05%RCUSArcus Biosciences0.00%+0.21%-7.56%+16.22%+159.55%TLXTelix Pharmaceuticals0.00%-7.88%-10.32%+44.58%-42.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNLIDenali Therapeutics 2.87Moderate Buy$34.2576.82% UpsideESPREsperion Therapeutics 2.00Hold$5.5477.00% UpsideRCUSArcus Biosciences 2.55Moderate Buy$33.8944.27% UpsideTLXTelix Pharmaceuticals 2.78Moderate Buy$21.13120.74% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, TLX, DNLI, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$40.00 ➝ $35.005/22/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.005/18/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00 ➝ $35.005/14/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.005/11/2026RCUSArcus Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$20.00 ➝ $22.005/11/2026DNLIDenali Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/8/2026DNLIDenali Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.005/7/2026RCUSArcus Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $34.005/4/2026ESPREsperion Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/4/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026ESPREsperion Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNLIDenali Therapeutics$330.53M9.30N/AN/A$5.84 per share3.32ESPREsperion Therapeutics$418.24M1.93N/AN/A($1.20) per share-2.61RCUSArcus Biosciences$247M11.96N/AN/A$4.17 per share5.63TLXTelix Pharmaceuticals$803.79M4.04$0.04 per share224.60$1.23 per share7.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)ESPREsperion Therapeutics-$22.68M-$0.06N/A14.232.540.12%-0.14%0.12%8/4/2026 (Estimated)RCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)TLXTelix Pharmaceuticals-$7.12MN/AN/A56.29N/AN/AN/AN/AN/ALatest ESPR, TLX, DNLI, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ESPREsperion Therapeutics-$0.02-$0.10-$0.08-$0.10$84.52 million$80.10 million5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million3/10/2026Q4 2025ESPREsperion Therapeutics$0.23$0.22-$0.01$0.22$165.12 million$168.45 million2/26/2026Q4 2025DNLIDenali Therapeutics-$0.75-$0.73+$0.02-$0.73$2.86 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNLIDenali TherapeuticsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNLIDenali Therapeutics0.019.289.28ESPREsperion TherapeuticsN/A1.531.18RCUSArcus Biosciences0.194.044.04TLXTelix Pharmaceuticals1.081.431.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNLIDenali Therapeutics92.92%ESPREsperion Therapeutics47.39%RCUSArcus Biosciences92.89%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDNLIDenali Therapeutics12.50%ESPREsperion Therapeutics1.60%RCUSArcus Biosciences9.60%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableESPREsperion Therapeutics200257.43 million253.31 millionOptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableTLXTelix Pharmaceuticals1,184339.38 millionN/AN/AESPR, TLX, DNLI, and RCUS HeadlinesRecent News About These CompaniesTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What HappenedMay 24 at 3:51 AM | americanbankingnews.comTelix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving UpMay 18, 2026 | seekingalpha.comIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms DosingMay 18, 2026 | globenewswire.comTelix Pharmaceuticals Ltd ADR TLXMay 17, 2026 | morningstar.comMTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesMay 15, 2026 | globenewswire.comTelix Issues New Shares to Complete Deferred ImaginAb Acquisition PaymentMay 10, 2026 | theglobeandmail.comMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic SurgeryMay 8, 2026 | businesswire.comChristian Behrenbruch Acquires 33,435 Shares of Telix Pharmaceuticals (NASDAQ:TLX) StockMay 7, 2026 | insidertrades.comInsider Buying: Telix Pharmaceuticals (NASDAQ:TLX) CEO Buys 33,435 Shares of StockMay 6, 2026 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) CEO Christian Behrenbruch Acquires 34,500 SharesMay 6, 2026 | marketbeat.comNew Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCCMay 4, 2026 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 - SlideshowMay 2, 2026 | seekingalpha.comInsider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of SharesMay 1, 2026 | finance.yahoo.comTelix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of "Moderate Buy" from AnalystsMay 1, 2026 | marketbeat.comTLX101-Px (Pixlumi®) MAA Accepted in EuropeApril 30, 2026 | globenewswire.comHow TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) InvestorsApril 30, 2026 | finance.yahoo.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 TranscriptApril 30, 2026 | seekingalpha.comTelix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears EndApril 29, 2026 | marketbeat.comOPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate CancerApril 29, 2026 | globenewswire.comEducational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio ApproachApril 27, 2026 | globenewswire.comWhat's driving the wild swings in Telix shares?April 23, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESPR, TLX, DNLI, and RCUS Company DescriptionsDenali Therapeutics NASDAQ:DNLI$19.37 +0.73 (+3.92%) As of 10:27 AM EasternDenali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Esperion Therapeutics NASDAQ:ESPR$3.13 0.00 (0.00%) As of 10:27 AM EasternEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Arcus Biosciences NYSE:RCUS$23.49 +0.06 (+0.26%) As of 10:28 AM EasternArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Telix Pharmaceuticals NASDAQ:TLX$9.57 +0.10 (+1.06%) As of 10:27 AM EasternTelix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Alphabet Just Unveiled Its Most Ambitious AI Lineup Yet Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
